Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to $0.2.

  • Ptc Therapeutics' EPS (Basic) rose 11438.85% to $0.2 in Q3 2025 from the same period last year, while for Sep 2025 it was $9.61, marking a year-over-year increase of 26178.45%. This contributed to the annual value of -$4.73 for FY2024, which is 4351.7% up from last year.
  • Per Ptc Therapeutics' latest filing, its EPS (Basic) stood at $0.2 for Q3 2025, which was up 11438.85% from -$0.83 recorded in Q2 2025.
  • Over the past 5 years, Ptc Therapeutics' EPS (Basic) peaked at $11.09 during Q1 2025, and registered a low of -$2.66 during Q2 2023.
  • For the 5-year period, Ptc Therapeutics' EPS (Basic) averaged around -$0.94, with its median value being -$1.76 (2023).
  • In the last 5 years, Ptc Therapeutics' EPS (Basic) plummeted by 8349.51% in 2021 and then surged by 102416.67% in 2025.
  • Ptc Therapeutics' EPS (Basic) (Quarter) stood at -$2.02 in 2021, then dropped by 16.83% to -$2.36 in 2022, then grew by 12.71% to -$2.06 in 2023, then skyrocketed by 58.38% to -$0.86 in 2024, then surged by 123.33% to $0.2 in 2025.
  • Its last three reported values are $0.2 in Q3 2025, -$0.83 for Q2 2025, and $11.09 during Q1 2025.